Sonnet BioTherapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Disclosure About Fair Value (Tables)

6 Months Ended

Jun. 30, 2016

Assets and liabilities measured at fair value on a recurring basis are summarized in the following tables according to FASB ASC 820 pricing levels.

	Fair Value Measurement Using
			Quoted prices
			in active		Significant
			markets of		other		Significant
			identical		observable		Unobservable
	Recorded		assets		inputs		Inputs
	value		(Level 1)		(Level 2)		(Level 3)
June 30, 2016
Assets:
Available-for-sale securities	$	11,480	$	11,480	$	-	$	-

Liabilities:
Embedded conversion feature		72,000		-		-		72,000
Warrants		30,507						30,507
December 31, 2015
Assets:
Available-for-sale securities	$	31,322	$	31,322	$	-	$	-

Liabilities:
Embedded conversion feature		1,094,300		-		-		1,094,300
Warrants		137,308						137,308